An update on the NCRI AML20 trial

During the 2nd National Cancer Research Institute (NCRI) AML Academy meeting, which took place on October 8–9, 2020, we spoke to Executive Steering Committee Member Charles Craddock, Queen Elizabeth Hospital, Birmingham, UK, about the NCRI AML20 trial.

In this video, Charles Craddock describes the three main questions the trial aims to address, including whether the addition of venetoclax can improve the activity of CPX-351 in adults with AML. He also discusses the challenges of opening the trial due to COVID-19.